Brilique 90 mg Orodispersible Tablets
- Name:
Brilique 90 mg Orodispersible Tablets
- Company:
AstraZeneca Pharmaceuticals (Ireland) DAC
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 26/09/19

Click on this link to Download PDF directly
AstraZeneca Pharmaceuticals (Ireland) DAC
 DAC.gif)
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 26 September 2019 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Addition of warning relating to interference with platelet function tests to diagnose heparin induced thrombocytopenia (HIT), update of HPRA adverse event reporting details, update to date of revision
Updated on 26 September 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Change to MA holder contact details
Free text change information supplied by the pharmaceutical company
Blue = Addition
Red = Deletion
2. What you need to know before you take Brilique
Warnings and Precautions
…..
If you are taking both Brilique and heparin:
- Your doctor may require a sample of your blood for diagnostic tests if they suspect a rare platelet disorder caused by heparin. It is important that you inform your doctor that you are taking both Brilique and heparin, as Brilique may affect the diagnostic test.
4. Possible side effects
Reporting of side effects
UK
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Ireland
HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: medsafety@hpra.ie
Malta
ADR Reporting
Website: www.medicinesauthority.gov.mt/adrportal
…..
6. Contents of the pack and other information
Marketing Authorisation Holder and Manufacturer
…..
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
United Kingdom
AstraZeneca UK Ltd
Tel: + 44 1582 836 836
Ireland
AstraZeneca Pharmaceuticals (Ireland) DAC
Tel: + 353 1609 7100
Malta
Associated Drug Co. Ltd
Tel: + 356 2277 8000
This leaflet was last revised in September 2019.
Updated on 14 June 2019 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 14 June 2019 SPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
- Improved presentation of SPC
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.5: Addition of Thrombotic Thrombocytopenic Purpura wording.
Section 4.8: Thrombotic Thrombocytopenic Purpura (unknown) side effect added to AE table.
Section 10: date updated.
Additional minor editorial revisions were made throughout the SmPC.
Updated on 28 November 2018 PIL
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
- Improved presentation of PIL
Updated on 28 November 2018 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.9 - Overdose
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
- Change to improve clarity and readability
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 2: addition of sodium content wording.
Section 4.2: deletion of wording for renal dialysis.
Section 4.4: updated wording for bradycardia added.
Section 4.4: Addition of ‘stroke’ for premature discontinuation.
Section 4.9: wording for dialysis clarified.
Section 5.2: haemodialysis wording added to the ‘Renal impairment’ subheading.
Section 10: date updated.
Additional minor editorial revisions were made throughout the SmPC.
Updated on 3 August 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - date of revision
Updated on 3 August 2018 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.4
Surgery
Change from 7 to 5 days where ticagrelor should be discontinued prior to surgery
Section 10
Date of revision changed to 26th July 2018.
Updated on 29 May 2018 SPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.5 Editorial changes to placement of information on grapefruit juice. Addditional information relating to interaction between morphine and oral P2Y12 inhibitors, including ticagrelor and its active metabolite.
Section 4.8 Addition of comma and update UK ADR reporting details in line with latest version.
Section 5.3 Addition of comma.
Section 10 Updated date of revision.
Updated on 29 May 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 3 January 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 3 January 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)